Join
Live feed
·
PRReleasevia Quantisnow
YD Bio Limited logo

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

ByQuantisnow·Wall Street's wire, on your screen.
YDES· YD Bio Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track YDES (YD Bio Limited) and more on Quantisnow.